Clinical assessment of possible associations between long-term glucose-lowering effects of liraglutide and basal insulin combination therapy and remaining beta-cell function

Clinical assessment of possible associations between long-term glucose-lowering effects of liraglutide and basal insulin combination therapy and remaining beta-cell function - Liraglutide/basal insulin combination and beta-cell function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028374

Enrollment

100

Registered

2017-07-26

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes continuing basal insulin/liraglutide combination therapy for 54 weeks

Exclusion criteria

Exclusion criteria: 1) Patients receiving an additional oral anti-diabetes drug or prandial insulin within 54 weeks after initiation of basal insulin and liraglutide combination therapy 2) Patients with with type 1 diabetes, pregnancy, pancreatic disease, liver disease, renal disease, or malignancy 3) Patients with severe renal failure (Ccr less than 30ml/min) and/or those taking dialysis 4) Patients receiving diabetogenic agents such as steroids 5) Patients with death within 54 weeks after initiation of basal insulin/liraglutide therapy 6) Patients with psychiatric disorders

Design outcomes

Primary

Measure	Time frame
Comparison of remaining pancreatic beta-cell function between patients achieving HbA1c <7% by liraglutide/basal insulin combination therapy	—

Countries

Japan

Contacts

Public ContactDaisuke Yabe

Kansai Electric Power Medical Research Institute Yutaka Seino Distinguished Center for Diabetes Research

ydaisuke-kyoto@umin.ac.jp078-303-6090

Outcome results